Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A195940 from our risk checks.
HK inno.N Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩36,000.00 |
52 Week High | ₩47,450.00 |
52 Week Low | ₩27,900.00 |
Beta | 0 |
11 Month Change | -4.51% |
3 Month Change | -2.04% |
1 Year Change | 21.01% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -47.45% |
Recent News & Updates
Recent updates
Shareholder Returns
A195940 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | -4.0% | 2.3% | -0.05% |
1Y | 21.0% | 10.9% | 6.0% |
Return vs Industry: A195940 exceeded the KR Pharmaceuticals industry which returned 9% over the past year.
Return vs Market: A195940 exceeded the KR Market which returned 5% over the past year.
Price Volatility
A195940 volatility | |
---|---|
A195940 Average Weekly Movement | 5.2% |
Pharmaceuticals Industry Average Movement | 3.8% |
Market Average Movement | 4.9% |
10% most volatile stocks in KR Market | 11.1% |
10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A195940 has not had significant price volatility in the past 3 months.
Volatility Over Time: A195940's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1984 | 1,695 | Dal-Won Kwak | www.inno-n.com |
HK inno N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, non-small cell lung cancer, and mesothelioma, and colorectal cancer; and nutrition and intravenous nutrition.
HK inno.N Corporation Fundamentals Summary
A195940 fundamental statistics | |
---|---|
Market cap | ₩1.02t |
Earnings (TTM) | ₩41.49b |
Revenue (TTM) | ₩839.63b |
0.0x
P/E Ratio0.0x
P/S RatioIs A195940 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A195940 income statement (TTM) | |
---|---|
Revenue | ₩839.63b |
Cost of Revenue | ₩491.45b |
Gross Profit | ₩348.18b |
Other Expenses | ₩306.69b |
Earnings | ₩41.49b |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did A195940 perform over the long term?
See historical performance and comparison